REGENERON PHARMACEUTICALS, INC. REGN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
9.21
Altman Z″ — distress risk · safe
8.2%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $14.3B | $4.5B | — | — | $31.3B |
| 2024 | $14.2B | $4.4B | — | — | $29.4B |
| 2023 | $13.1B | $4.0B | — | — | $26.0B |
| 2022 | $12.2B | $4.3B | — | — | $22.7B |
| 2021 | $16.1B | $8.1B | — | — | $18.8B |
| 2020 | $8.5B | $3.5B | — | — | $11.0B |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 9.21 (safe)
- Working capital / assets 0.337
- Retained earnings / assets 0.883
- EBIT / assets 0.088
- Equity / liabilities 3.36
Source: SEC EDGAR filings · CIK 0000872589 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.